Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Licenses RNAi Patents to Invitrogen, Cell Signaling Technology, Cenix

NEW YORK, Jan. 13 (GenomeWeb News) - Alnylam Pharmaceuticals has licensed RNA interference patents to Invitrogen, Cell Signaling Technology, and Cenix Bioscience, the company said today.


Invitrogen, headquartered in Carlsbad, Calif., has obtained a license to provide research products and services under a patent family owned by Alnylam that covers the use of short double-stranded RNAs to mediate RNAi and that includes European patent 1 144 623.


Cell Signaling Technology, located in Beverly, Mass., has licensed one RNAi patent to provide research products. Following an initial payment, the company will pay Alnylam annual fees and royalties on product sales.


Cenix BioScience, of Dresden, Germany, has licensed one RNAi patent to market its RNAi research services. It will pay Alnylam annual fees and royalties on the services it provides. In addition, Cenix will provide Alnylam with its expertise in designing and testing small interfering RNAs.


The licenses were granted by Ribopharma of Kulmbach, Germany, one of Alnylam's two operating units.


The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.